WallStreetZenWallStreetZen

NASDAQ: IMAB
I Mab Stock

$1.63+0.00 (+0%)
Updated Jul 16, 2024
IMAB Price
$1.63
Fair Value Price
$3.09
Market Cap
$131.61M
52 Week Low
$1.16
52 Week High
$3.17
P/E
-0.67x
P/B
0.55x
P/S
40.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.82M
Earnings
-$206.73M
Gross Margin
100%
Operating Margin
-5,299.42%
Profit Margin
-5,302%
Debt to Equity
0.52
Operating Cash Flow
-$184M
Beta
0.89
Next Earnings
Aug 15, 2024
Ex-Dividend
N/A
Next Dividend
N/A

IMAB Overview

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IMAB ($1.63) is undervalued by 47.19% relative to our estimate of its Fair Value price of $3.09 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
IMAB ($1.63) is significantly undervalued by 47.19% relative to our estimate of its Fair Value price of $3.09 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
IMAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMAB due diligence checks available for Premium users.

Be the first to know about important IMAB news, forecast changes, insider trades & much more!

IMAB News

Valuation

IMAB fair value

Fair Value of IMAB stock based on Discounted Cash Flow (DCF)
Price
$1.63
Fair Value
$3.09
Undervalued by
47.19%
IMAB ($1.63) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMAB ($1.63) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMAB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IMAB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.67x
Industry
-18x
Market
31.71x

IMAB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.55x
Industry
6.51x
IMAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IMAB's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
IMAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IMAB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$368.5M
Liabilities
$126.2M
Debt to equity
0.52
IMAB's short-term assets ($323.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMAB's short-term assets ($323.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMAB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
IMAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IMAB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
IMAB$131.61M0.00%-0.67x0.55x
RAPT$130.89M+5.04%-1.22x1.00x
IMUX$133.32M+8.82%-0.81x1.60x
VXRT$129.09M+7.99%-1.38x2.32x
ATHA$128.78M0.00%-1.10x1.21x

I Mab Stock FAQ

What is I Mab's quote symbol?

(NASDAQ: IMAB) I Mab trades on the NASDAQ under the ticker symbol IMAB. I Mab stock quotes can also be displayed as NASDAQ: IMAB.

If you're new to stock investing, here's how to buy I Mab stock.

What is the 52 week high and low for I Mab (NASDAQ: IMAB)?

(NASDAQ: IMAB) I Mab's 52-week high was $3.17, and its 52-week low was $1.16. It is currently -48.58% from its 52-week high and 40.52% from its 52-week low.

How much is I Mab stock worth today?

(NASDAQ: IMAB) I Mab currently has 185,613,662 outstanding shares. With I Mab stock trading at $1.63 per share, the total value of I Mab stock (market capitalization) is $131.61M.

I Mab stock was originally listed at a price of $13.80 in Jan 21, 2020. If you had invested in I Mab stock at $13.80, your return over the last 4 years would have been -88.19%, for an annualized return of -41.38% (not including any dividends or dividend reinvestments).

How much is I Mab's stock price per share?

(NASDAQ: IMAB) I Mab stock price per share is $1.63 today (as of Jul 16, 2024).

What is I Mab's Market Cap?

(NASDAQ: IMAB) I Mab's market cap is $131.61M, as of Jul 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

I Mab's market cap is calculated by multiplying IMAB's current stock price of $1.63 by IMAB's total outstanding shares of 185,613,662.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.